First report of trastuzumab treatment after postoperative Takotsubo cardiomyopathy.
Fiche publication
Date publication
juillet 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Pr MATHELIN Carole, Pr IMPERIALE Alessio, Dr BURGY Mickaël
Tous les auteurs :
Burgy M, Brossat H, Barthelemy P, Imperiale A, Trinh A, Hazam CA, Bergerat JP, Mathelin C
Lien Pubmed
Résumé
BACKGROUND: Trastuzumab is a humanized monoclonal antibody used for the treatment of HER2-positive breast cancer. Cardiotoxicity is a well-known adverse event of trastuzumab use but little has been documented regarding its use in patients with a history of cardiac disease. CASE REPORT: We describe a case in which trastuzumab treatment was administered to a 40-year-old female patient with early breast cancer after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. After one year of follow-up with close monitoring by echocardiography, there have been no heart-related symptoms. Additional surgery was performed because of positive resection margins at first surgery, without complications, despite the risk of recurrence of Takotsubo cardiomyopathy. CONCLUSION: Trastuzumab can be safely administered after acute heart failure secondary to postoperative Takotsubo cardiomyopathy.
Référence
Anticancer Res. 2014 Jul;34(7):3579-82.